AU2011203526A1 — Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Assigned to Teva Womens Health Inc · Expires 2011-08-04 · 15y expired
What this patent protects
C:WRonbl\DCC\AMT\373%36_ LDOC6/07/2011 The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a …
USPTO Abstract
C:WRonbl\DCC\AMT\373%36_ LDOC6/07/2011 The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.